Iron Deficiency Treatment: Drug Names & Brands in India
Oral and IV iron formulations used for iron deficiency in India, their generic names, NLEM status, and what a hospital pharmacy needs to stock.
This piece runs through the actual generic categories behind these iron deficiency names, the government programme driving oral iron demand nationally, and closes on why reliable in-house stocking of this drug class matters for hospital revenue and patient continuity.
What are the main oral iron deficiency names used in India?
First-line oral therapy for iron deficiency anemia in India relies on ferrous sulfate, ferrous fumarate, and ferrous ascorbate, all off-patent generic salts manufactured by dozens of Indian companies, plus carbonyl iron, a distinct elemental-iron form some clinicians prefer for its side-effect profile. These generic names, not brand names, are what actually determine a hospital pharmacy's core iron stock.
Iron and folic acid combination tablets specifically are the backbone of India's national anaemia programme and are manufactured at enormous volume for government procurement as well as private retail, keeping per-strip prices low across virtually every registered brand.
What intravenous iron formulations are used when oral iron fails?
Intravenous iron becomes clinically necessary when a patient cannot absorb or tolerate oral iron. This is most common in inflammatory bowel disease, chronic kidney disease, bariatric surgery patients, or late-pregnancy anaemia needing rapid correction. The IV formulations used in India are iron sucrose, ferric carboxymaltose, and iron dextran, each a distinct molecule with a different infusion protocol and risk profile, not interchangeable brand variants of the same drug.
Ferric carboxymaltose in particular has become widely used in Indian obstetric and nephrology practice because it allows a large iron dose in a single infusion, compared with the multiple sittings iron sucrose typically requires, a genuine clinical trade-off a treating physician weighs case by case.
Why does iron deficiency anemia matter so much in India specifically?
India carries one of the highest anaemia burdens globally, and it is a declared public health priority, not a minor nutritional gap. The most recent National Family Health Survey found anaemia in 67% of children aged 6-59 months, 59% of adolescent girls aged 15-19, 31% of adolescent boys, and 57% of women of reproductive age.
The Anemia Mukt Bharat programme, launched by the Government of India in 2018, targets these exact groups through iron-folic acid prophylaxis across six life-stage interventions, making iron supplementation one of the single highest-volume drug categories moving through India's public and private healthcare system combined.
How does government policy shape which iron formulations get stocked?
Anemia Mukt Bharat's own dosing guidance differs in places from WHO recommendations on regimen and dose. This reflects India-specific programme design, not a universal standard, and matters for a hospital aligning its protocol with the national programme it reports into. Iron-folic acid tablets under this programme are procured at national scale, keeping the generic formulation cheap regardless of which brand a pharmacy stocks.
This government-driven volume is also why iron-folic acid combinations remain one of the most consistently available generic categories through Jan Aushadhi Kendras, giving a hospital pharmacy a reliable low-cost sourcing channel alongside standard trade purchasing.
How do the main iron deficiency formulations compare?
Five generic categories cover almost every iron deficiency prescription seen in Indian practice, split between oral first-line therapy and IV options reserved for oral-intolerant or urgent cases, summarised in the table below for quick reference by a prescribing clinician or procurement team.
| Formulation type | Generic examples | Typical use case |
|---|---|---|
| Oral ferrous salt | Ferrous sulfate, ferrous fumarate, ferrous ascorbate | First-line for most iron deficiency anaemia |
| Oral elemental iron | Carbonyl iron | Alternative for patients with GI intolerance to salts |
| IV iron, multi-dose | Iron sucrose | CKD, oral-intolerant patients needing staged correction |
| IV iron, single high-dose | Ferric carboxymaltose | Rapid correction, e.g. late pregnancy, pre-surgical |
| IV iron, alternative | Iron dextran | Used where sucrose or carboxymaltose access is limited |
This reflects clinical use category, not brand hierarchy. Every generic here is made under multiple registered brand names across Indian companies, and none is a single-source product.
Why does reliable iron stock matter to a hospital's own pharmacy?
Iron deficiency anaemia is one of the highest-frequency diagnoses in Indian OPD and antenatal clinics, which makes oral iron tablets a genuinely high-turnover, low-margin-risk SKU for any hospital pharmacy to hold. A stockout on something this routine sends the patient to the nearest chemist for a refill that never comes back to the hospital counter.
IV iron carries a sharper version of the same problem: a patient referred for ferric carboxymaltose infusion who finds the hospital pharmacy doesn't stock it either delays treatment or gets the drug from an outside source, breaking the continuity between the ordering physician and the dispensing pharmacy. Medyzen's managed hospital pharmacy approach is built to prevent exactly this kind of routine-but-critical stockout, and the broader revenue impact of losing these prescriptions is covered in prescription leakage and hospital revenue loss. The inventory discipline that keeps a fast-moving generic like iron from becoming dead stock is covered in pharmacy inventory management.
Sources
- 1Anemia Mukt Bharat Index: Methodology and State Rankings of Iron and Folic Acid Supplementation Coverage in India — National Institutes of Health, National Library of Medicine
- 2Coverage of iron and folic acid supplementation in India: progress under the Anemia Mukt Bharat strategy 2017-20 — National Institutes of Health, National Library of Medicine
- 3A Comprehensive Review of Iron Prophylaxis in the National Anemia Control Programme in India — medRxiv preprint, cites ICMR/NITI Aayog programme design
- 4National Pharmaceutical Pricing Authority — scheduled formulation pricing, Government of India
- 5Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. Formulation choice and dosing for iron deficiency are clinical decisions made by the treating physician based on the individual patient's diagnosis and tolerance.
FAQ
Frequently asked questions
Oral ferrous salts, principally ferrous sulfate, ferrous fumarate and ferrous ascorbate, are the most widely prescribed first-line therapy, distributed at national scale through India's Anemia Mukt Bharat programme.
Intravenous iron (iron sucrose, ferric carboxymaltose, or iron dextran) is used when a patient cannot tolerate or adequately absorb oral iron, commonly in inflammatory bowel disease, chronic kidney disease, or when rapid correction is needed such as in late pregnancy.
Very common. The latest National Family Health Survey found anaemia in 57% of women of reproductive age and 67% of children aged 6-59 months, among the highest burdens recorded globally.
Neither is universally "better"; ferric carboxymaltose allows a larger iron dose in a single infusion while iron sucrose typically requires multiple sittings, and the choice depends on the patient's clinical situation as determined by the treating physician.
It is a Government of India strategy launched in 2018 to reduce anaemia prevalence across six population groups through iron-folic acid supplementation, part of six programmatic interventions delivered nationally.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.